An increased risk of Parkinson's disease after melanoma diagnosis has been described [49], [50] and is thought to occur due to increased alpha-synuclein expression in melanocytic lesions [51]–[53] that may interact with cell cycle regulators [54]. Here, SNCA is linked to Parkinson disease.